HMOX1 and prostate carcinoma: BIP expression in clinical specimens has been correlated with tumor survival, chemoresistance and poor prognosis23,24, and its localization to the cell surface of prostate cancer cells has been linked to the activation of HO-1 regulator Nrf2, and resistance to ER-stress induced apoptosis25.